Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo
et al
Thyroid
.
2021 Feb;31(2):330-331.
doi: 10.1089/thy.2020.0245.
Epub 2020 Oct 2.
Authors
Laura Agate
1
,
Luciana Puleo
1
,
Carlotta Giani
1
,
Laura Valerio
1
,
Eleonora Molinaro
1
,
Rossella Elisei
1
Affiliation
1
Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
PMID:
32723011
DOI:
10.1089/thy.2020.0245
No abstract available
Publication types
Comment
MeSH terms
Humans
Phenylurea Compounds / adverse effects
Quinolines* / adverse effects
Thyroid Neoplasms* / drug therapy
Substances
Phenylurea Compounds
Quinolines
lenvatinib